Kiniksa Pharmaceuticals, Ltd. (KNSA) ownership: Entities managed by Baker Bros. Advisors LP 19% · institutions 55% · index and ETF funds 3% (13F 2026-03-31). Insider activity, 90 days: 1 sales, 0 open-market buys. SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| FMR (Fidelity) | 6823700.00 | $328.56M | 8.3% | 2026-03-31 |
| Rubric Capital Management LP | 3750000.00 | $180.56M | 4.6% | 2026-03-31 |
| Vanguard | 3164153.00 | $152.35M | 3.8% | 2026-03-31 |
| Baker BROS. Advisors LP | 2826246.00 | $136.08M | 3.4% | 2026-03-31 |
| Tang Capital Management LLC | 2259889.00 | $108.81M | 2.7% | 2026-03-31 |
| Acadian Asset Management | 1336313.00 | $64.32M | 1.6% | 2026-03-31 |
| Fairmount Funds Management LLC | 1319688.00 | $54.44M | 1.6% | 2026-03-31 |
| Morgan Stanley | 997786.00 | $48.04M | 1.2% | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-19 | |
| Sell | null | 2026-08-01 | |
| Sell | null | 2026-08-01 | |
| Sell | null | 2026-08-01 | |
| Sell | null | 2026-07-29 | |
| Sell | null | 2026-07-29 | |
| Sell | null | 2026-07-01 | |
| Sell | null | 2026-07-01 |
Back to KNSA overview · KNSA earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.